results with unprecedented speed and efficiency. We provide labs with a solution that reduces the time for a genetic diagnosis from two working days to just two hours, cuts test costs by 50%, and increases diagnostic sensitivity to over 98%. Our technology integrates seamlessly into existing lab procedures, eliminating switching costs for our customers.

OaCP is a post-revenue company with significant market validation and a clear path to scale. Commercial Success: We have already generated over $1 million in cumulative sales to hospitals and distributors. Strategic Partnership: We have a key commercial partnership with Roche, accelerating our market entry into 10+ countries, beginning with Italy and Spain. Robust IP & Regulatory Approval: Our technology is protected by granted patents in the USA, EU, China, and India. Our products have received IVDR certification, clearing them for sale in the European market.

We are addressing the $40 billion molecular diagnostics market, with immediate applications in oncology, veterinary pathology, and microbiology.

We are raising $2.7 million to fuel our next stage of growth. The capital will be used to: Secure FDA 510(k) clearance to enter the U.S. market. Aggressively expand sales and distribution through our partnership with Roche and other channels. Consolidate our IP and expand our product lines.

Led by a founding team with over 100 years of combined experience in science, diagnostics, and business development, OaCP is uniquely positioned to become a market leader. Join us in our mission to create a world with less time for diagnosis and more time for life.